Can single positive core prostate cancer at biopsy be considered a low-risk disease?
Hayato Yamamoto(Hirosaki University), Chikara Οhyama(Hirosaki University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Tomoyuki Kato(Aichi Cancer Center), Norihiko Tsuchiya(Yamagata University), Shintaro Narita(Akita University), Takuya Koie(Hirosaki University), Takamitsu Inoue(International University of Health and Welfare), Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Yoichi Arai(Japan Atomic Energy Agency), Teppei Ookubo(Tohoku University), Tatsuo Tochigi(Miyagi Prefectural Hospital Organization), Tomonori Habuchi(Akita University)
Cited by 4
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
|Journal of Clinical Oncology|2013|253